Overview

A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

Status:
Not yet recruiting

Trial end date:
2022-07-03

Target enrollment:

Participant gender:

Summary

The objective of this study is to compare the safety and efficacy of tanfanercept ophthalmic solution 0.25% with placebo for the treatment of the signs and symptoms of dry eye.

Phase:

Phase 3

Details

Lead Sponsor:

HanAll BioPharma Co., Ltd.

Collaborator:

Daewoong Pharmaceutical Co. LTD.

Treatments:

Ophthalmic Solutions